Sixty Degree Capital

Sixty Degree Capital investment thesis

Headqaurters: San Francisco, CA, USA Subsector: MedTech Everside Health Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Everside Health’s Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Everside Health’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. Everside Health is working toward a Marketing Authorization Application

Sixty Degree Capital team (7)

Partners and principals at Sixty Degree Capital:

• Robin Gao — sweet spot $1.5M
• Kenneth Grisé — sweet spot $1.5M
• Robert Guo — sweet spot $1.5M
• Cheryl Kuai — sweet spot $1.5M
• Thomas (Tianyu) Piao — sweet spot $1.5M
• Sintia Teichman — sweet spot $1.5M
• Yi (Lily) Li — sweet spot $1.5M

Sixty Degree Capital portfolio companies

Companies listed on Sixty Degree Capital's public materials include: Our Portfolio, Our Insights, Spotlight, All, Healthcare, Technology, Join the conversation., Linkedin, info@sixtydegreecapital.com, Headqaurters:, Subsector:, View our website.

Is Sixty Degree Capital a fit for your round?

Upload your pitch deck and see whether anyone at Sixty Degree Capital appears in your top matches.